GW Pharmaceuticals plc today announces that Sativex® oromucosal spray has been approved in the Czech Republic as a treatment for spasticity due to Multiple Sclerosis (MS).
This approval follows GW's announcement on 22nd March 2011 that the European Mutual Recognition Procedure had successfully completed with all six countries involved recommending approval. The countries involved in the MRP were Germany, Italy, Denmark, Sweden, Austria and the Czech Republic. The Czech Republic is the first of these countries to approve Sativex. The remaining countries involved in the MRP are expected to approve Sativex in the coming months... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814